FORWARD INQUIRIES TO:

SAFC Biosciences
Bruce Lehr
Director of Marketing
+ 1.913.227.6790

MEDIA INQUIRIES TO:

Mr. Mark Button
Impress Public Relations
+ 408.310.2168
mark@impress-pr.com

SAFC BIOSCIENCES™ COMPLETES CONVERSION OF LENEXA MEDIA

MILLING FACILITY TO ANIMAL COMPONENT FREE
Customer Demand for ACF Manufacturing Drives Aggressive Conversion Program

St. Louis, MO – March 26, 2009 - SAFC Biosciences™, a leading provider of cell culture
materials and services for upstream and downstream processes in the biopharmaceutical
industry and a business segment within SAFC®, a member of the Sigma-Aldrich Group
(NASDAQ: SIAL), today announced it has completed the conversion of its dry powder cell
culture media continuous milling production site in Lenexa, Kansas to animal component
free (ACF) status. Part of a global facility conversion strategy, this is the first of several
similar conversions planned by SAFC Biosciences to support growing customer
requirements for ACF manufacturing.

“As a leader in the biological manufacturing market, our customer-centric approach aligns
closely with expanding customer requirements for safer ACF manufacturing models,”
commented Bruce Lehr, Director of Marketing at SAFC Biosciences. “The comprehensive
conversion of this facility to ACF status is driven by market requirements that are influenced
by regulatory guidance for reducing animal component risk, and by an expanding focus on
‘second generation’ biologics-based drugs that require ACF production platforms.”
(more)
Page 2

During this facility’s ACF conversion, extensive cleaning conversion protocol was completed
and systems and procedures were reviewed and modified appropriately. Major factors
addressed during this process included comprehensive:

• Cleaning protocol and documentation;

• Facility analysis on air, personnel, equipment and process flows;
• Raw material procedures - from receipt, inspection/sampling, quarantine and storage to
release;
• SOPs/Ops/Procedures review against ACF requirements, with changes implemented to
cover product sampling, personnel and product flows, and cleaning;
• Personnel training records review and pertinent training updates prior to ACF
conversion;
• Risk analysis performed on all equipment and components used in ACF areas;
• ACF status and manufacturing information collected on all raw materials;
• Contamination remediation plan instituted for any system breech, including provisions for
equipment decontamination, cleaning procedures, personnel and process flows,
timelines and business continuity planning.

“Moving our Lenexa media milling facility to ACF status was motivated by SAFC
Bioscience’s dedication to understanding our biopharmaceutical client’s requirements and
providing them with appropriate solutions to fit those needs,” said SAFC Biosciences
President, Rod Kelley. “Conversion of this facility is part of our Company’s continuing
strategy to offer expertise and appropriate manufacturing processes that are expected to
help global customers mitigate risk, increase operational efficiencies and meet regulatory
requirements. Conversion of additional facilities to ACF status is scheduled for completion
within the next 12 months in Europe and the United States.”

(more)
Page 3

About SAFC: SAFC® is the custom manufacturing and services group within Sigma-Aldrich that
focuses on high-purity inorganics for high technology applications, cell culture products and services
for biopharmaceutical manufacturing, biochemical production and the manufacturing of complex,
multi-step organic synthesis of APIs and key intermediates. SAFC has manufacturing facilities around
the world dedicated to providing manufacturing services for companies requiring a reliable partner to
produce their custom manufactured materials. SAFC has four focus areas – SAFC Pharma™, SAFC
Supply Solutions®, SAFC Biosciences™, and SAFC Hitech™ – and had annual sales of $624 million
in 2008. SAFC is one of the world’s 10 largest fine chemical businesses. For more information about
SAFC, visit www.safcglobal.com.

About SAFC Biosciences: Headquartered in Lenexa, Kansas, SAFC Biosciences is a leading

provider of cell culture materials and development services for upstream and downstream processes
in the biopharmaceutical industry. Providing an integrated services package in mammalian cell culture
media development, along with analytical and regulatory support, SAFC Biosciences employs a
wealth of industry experience and scientific know-how to deliver reliable, consistent solutions that
accelerate customer success - from development through to commercialization. The unit has a 35-
year history as a manufacturing partner providing leading biopharmaceutical companies with the
broadest range of highly customized products and services possible. SAFC Biosciences has six
production facilities in the United States, Europe and Australia, and employs 600 people.

About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and High Technology company. Its
chemical and biochemical products and kits are used in scientific research, including genomic and
proteomic research, biotechnology, pharmaceutical development and as key components in
pharmaceutical, diagnostic and other high technology manufacturing. The Company has customers in
life science companies, university and government institutions, hospitals, and in industry. Over one
million scientists and technologists use its products. Sigma-Aldrich operates in 38 countries and has
7,900 employees providing excellent service worldwide. Sigma-Aldrich is committed to Accelerating
Customer Success through Innovation and Leadership in Life Science, High Technology and Service.
For more information about Sigma-Aldrich, please visit its award-winning Web site at
http://www.sigma-aldrich.com.

Cautionary Statement: This release contains forward-looking statements relating to future

performance, goals, strategic actions and initiatives and similar intentions and beliefs and other
statements regarding the Company’s expectations, goals, beliefs, intentions and the like, which
involve assumptions regarding the Company’s operations and conditions in the markets the Company
serves. The Company does not undertake any obligation to update these forward-looking statements.

SAFC®, SAFC Supply Solutions® and Sigma-Aldrich® are registered trademarks and SAFC Pharma®, SAFC Biosciences™ and
SAFC Hitech™ are trademarks of Sigma-Aldrich Biotechnology L.P. and Sigma-Aldrich Co.

###